NeoGenomics, Inc. shared new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies. The data was originally shared at the 67th American Society of Hematology (ASH) Annual Meeting, according to an announcement.
The poster, “Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,” evaluated outcomes using the Neo Comprehensive Myeloid panel, a next-generation sequencing (NGS) assay that provides a complete view of genomic changes in myeloid cancers. By assessing mutations and fusions in a single test, this CGP panel detects important genomic variants that may otherwise be missed, and supports diagnosis, prognosis, and therapy selection for diseases such as acute myeloid leukemia (AML), myelodysplastic neoplasms (MDS), and myeloproliferative neoplasms (MPN).
Researchers analyzed data from 533 patients with myeloid disorders, integrating NeoGenomics’ molecular results with clinical data from national health information exchanges. The analysis found that in about one-third of patients tested, CGP identified pathogenic changes earlier in their disease, leading to diagnostic reclassification in several cases. It also revealed rare but clinically significant fusions—including PDGFRA, PDGFRB, FGFR1, and JAK2—that helped guide targeted treatment decisions.
